Tisagenlecleucel-T
Tisagenlecleucel-T is a type of immunotherapy that is used in the treatment of certain types of cancer. It is a chimeric antigen receptor T cell (CAR-T) therapy, which involves modifying a patient's own T cells to express a receptor specific for a particular protein on the surface of cancer cells.
History[edit | edit source]
Tisagenlecleucel-T was developed by Novartis, a Swiss multinational pharmaceutical company. It was the first CAR-T therapy to be approved by the Food and Drug Administration (FDA) in the United States, receiving approval in August 2017 for the treatment of B-cell acute lymphoblastic leukemia (ALL) in pediatric and young adult patients.
Mechanism of Action[edit | edit source]
Tisagenlecleucel-T works by targeting a protein called CD19, which is found on the surface of B cells, including B-cell leukemias and lymphomas. The patient's T cells are collected and genetically modified to express a chimeric antigen receptor (CAR) that recognizes CD19. These modified T cells are then infused back into the patient, where they can recognize and kill CD19-expressing cancer cells.
Clinical Use[edit | edit source]
Tisagenlecleucel-T is used in the treatment of B-cell acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse in pediatric and young adult patients up to 25 years of age. It is also approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.
Side Effects[edit | edit source]
The most common side effects of tisagenlecleucel-T include cytokine release syndrome (CRS), which is a systemic inflammatory response that can lead to high fever, low blood pressure, and organ damage. Neurological toxicities are also common and can include confusion, seizures, and severe headaches.
Future Directions[edit | edit source]
Research is ongoing to expand the use of tisagenlecleucel-T to other types of cancer and to improve its safety and efficacy. This includes the development of next-generation CAR-T therapies that can target multiple antigens and the use of combination therapies with other types of immunotherapy.
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
